China News Service, September 12 (Reporter Chen Jing) In China, the annual incidence and mortality of lung cancer ranks first among malignant tumors.
The reporter learned on the 12th that the National Cancer Center has completed the screening of 400,000 lung cancer high-risk populations across the country and is actively building a national cancer prevention and control platform.
At the "2020 China Lung Cancer Prevention Summit Forum", researcher Li Ni, deputy director of the Office of Early Cancer Diagnosis and Treatment of the National Cancer Center, disclosed the above information and pointed out that the country attaches great importance to cancer screening, early diagnosis and treatment, including lung cancer. A series of cancer prevention and control policies incorporate cancer screening and early diagnosis and treatment into major national public health services; professional medical institutions actively implement the national strategic plan.
Professor Wang Yan, chief physician of the Department of Internal Medicine at the Cancer Hospital of the Chinese Academy of Medical Sciences, believes that drug selection should fully consider factors such as drug efficacy, safety, and economy.
Photo courtesy of the organizer
The reporter learned on the 12th that at the forum, many well-known experts from all over China focused on the current status and progress of diagnosis and treatment of lung cancer in China, and conducted in-depth discussions in multiple dimensions from strengthening early screening and early diagnosis, progress in precision treatment, and improving the availability of innovative drugs .
The forum will be broadcast live to doctors online.
It is understood that targeted therapy has opened a new era of precision treatment of lung cancer, and the rise of immunotherapy has also benefited many lung cancer patients.
Professor Wu Yilong, the life director of Guangdong Provincial People's Hospital, said that with the maturation and promotion of targeted therapy, immunotherapy and other precision treatment methods, the barriers to diagnosis and treatment of lung cancer continue to move forward, bringing greater survival benefits to patients.
"Gao Shugeng, vice president of the Cancer Hospital of the Chinese Academy of Medical Sciences, pointed out that the development of precision lung cancer treatment will help improve the survival rate and quality of life of lung cancer patients.
Gu Xuefei, director of the Medical Security Research Office of the Health Development Research Center of the National Health Commission, pointed out that the key to further improving the availability of new drugs lies in "increasing revenue and reducing expenditure."
Photo courtesy of the organizer
It is understood that in order to promote the availability of innovative drugs and fully meet the drug needs of patients, since 2016, China has successively updated the provincial medical insurance catalog, the national medical insurance catalog and the basic drug catalog, and more and more high-quality anti-cancer drugs To be included in medical insurance, the speed of drug approval is also accelerating.
Gu Xuefei, director of the Medical Security Research Office of the National Health Development Research Center of the National Health Commission, pointed out: "The key to further improving the availability of new drugs lies in'increasing revenue and reducing expenditure.' The'magic drug' will carry out payment method reforms to reduce unreasonable resource consumption."
Wu Yilong believes that the introduction of innovative drugs with significant curative effects into medical insurance can significantly improve the choice of treatment drugs for patients.
Gao Shugeng, vice president of the Cancer Hospital of the Chinese Academy of Medical Sciences, pointed out that to improve the accessibility of innovative drugs, we need not only medical insurance, but also commercial insurance, public welfare funds and other methods.
Faced with the continuous "advanced" of targeted drugs, how do lung cancer patients make choices during the treatment process?
Professor Wang Yan, chief physician of the Department of Internal Medicine, Cancer Hospital of the Chinese Academy of Medical Sciences, pointed out: “In general, better innovative drugs should be used at an earlier stage, and for individual patients, drug selection should fully consider drug efficacy, safety, and economy. Such factors cannot be generalized."
Strengthen cancer prevention and treatment, focusing on prevention.
Wu Jing, director of the Chronic Disease Center of the Chinese Center for Disease Control and Prevention, also said: “Everyone is the first person responsible for their own health. Take the initiative to take measures as early as possible, practice a healthy lifestyle, conduct regular cancer checkups, pay close attention to cancer danger signs, and accept standardization. Treatment is the key to lung cancer prevention and control.
It is understood that at present, the research on lung cancer targeted therapy has spread from common targets to rare targets. Professor Wu Yilong said that this will bring hope for treatment to these patients.
(Finish)